What's Happening?
Reflow Medical has announced positive six-month results from the DEEPER CORONARY study of its Spur Elute Sirolimus-Eluting Retrievable Stent System. Presented at EuroPCR 2026, the study evaluates the stent's safety and efficacy in treating coronary in-stent
restenosis (ISR). The results showed 100% freedom from major adverse cardiac events (MACE) and all-cause mortality among nine subjects. The Spur Elute system, featuring radially expandable spikes and a sirolimus drug coating, aims to maximize luminal diameter and reduce restenosis risk. These findings support further clinical evaluation of this innovative stent approach.
Why It's Important?
The promising results from the DEEPER CORONARY study highlight the potential of Reflow Medical's Spur Elute Stent System to improve treatment outcomes for patients with coronary artery disease. By offering a retrievable, sirolimus-eluting stent, the system addresses the limitations of permanent metallic implants, potentially reducing long-term complications. This innovation could lead to advancements in coronary interventions, providing cardiologists with new tools to manage complex cases of in-stent restenosis. The study's success may also encourage further research and development in retrievable stent technologies, ultimately benefiting patients with cardiovascular conditions.
